Wang Zhengjun, Ding Dongyi, Wang Jiaxing, Chen Ling, Dong Qingming, Khamrai Moumita, Zhou Yuyang, Ishii Akihiro, Sakata Kazuko, Li Wei, Du Jianyang, Vaithianathan Thirumalini, Zhou Fu-Ming, Liao Francesca-Fang
Department of Pharmacology, Addiction Science and Toxicology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Cells. 2025 Jun 4;14(11):843. doi: 10.3390/cells14110843.
To investigate how dysregulated transient receptor potential canonical channels (TRPCs) are associated with Alzheimer's disease (AD), we challenged primary neurons with amyloid-β (Aβ). Both the naturally secreted or synthetic Aβ oligomers (AβOs) induced long-lasting increased TRPC3 and downregulated the TRPC6 expression in mature excitatory neurons (CaMKIIα-high) via a Ca-dependent calcineurin-coupled NFAT transcriptionally and calpain-mediated protein degradation, respectively. The TRPC3 expression was also found to be upregulated in pyramidal neurons of human AD brains. The selective downregulation of the gene induced synaptotoxicity, while no significant effect was observed from the Trpc3-targeting siRNA, suggesting potentially differential roles of TRPC3 and 6 in modulating the synaptic morphology and functions. Electrophysiological recordings of mouse hippocampal slices overexpressing TRPC3 revealed increased neuronal hyperactivity upon the TRPC3 channel activation by its agonist. Furthermore, the AβO-mediated synaptotoxicity appeared to be positively correlated with the degrees of the induced dendritic Ca flux in neurons, which was completely prevented by the co-treatment with two pyrazole-based TRPC3-selective antagonists Pyr3 or Pyr10. Taken together, our findings suggest that the aberrantly upregulated TRPC3 is another ion channel critically contributing to the process of AβO-induced Ca overload, neuronal hyperexcitation, and synaptotoxicity, thus representing a potential therapeutic target of AD.
为了研究瞬时受体电位阳离子通道亚家族C成员(TRPCs)失调如何与阿尔茨海默病(AD)相关联,我们用β淀粉样蛋白(Aβ)刺激原代神经元。天然分泌或合成的Aβ寡聚体(AβOs)均可在成熟兴奋性神经元(钙/钙调蛋白依赖性蛋白激酶IIα高表达)中,分别通过钙依赖性钙调神经磷酸酶偶联的活化T细胞核因子(NFAT)转录和钙蛋白酶介导的蛋白质降解,诱导TRPC3持续增加并下调TRPC6表达。在人类AD脑的锥体神经元中也发现TRPC3表达上调。该基因的选择性下调诱导了突触毒性,而靶向Trpc3的小干扰RNA未观察到显著影响,这表明TRPC3和6在调节突触形态和功能方面可能具有不同作用。对过表达TRPC3的小鼠海马切片进行电生理记录显示,其激动剂激活TRPC3通道后神经元活动亢进增加。此外,AβO介导的突触毒性似乎与神经元中诱导的树突状钙通量程度呈正相关,用两种基于吡唑的TRPC3选择性拮抗剂Pyr3或Pyr10共同处理可完全阻止这种情况。综上所述,我们的研究结果表明,异常上调的TRPC3是另一种离子通道,对AβO诱导的钙超载、神经元过度兴奋和突触毒性过程起关键作用,因此是AD的一个潜在治疗靶点。